Medtronic (MDT)·Q3 2026 Earnings Summary
Medtronic Beats on Revenue & EPS, but Stock Drops 5% on Margin Pressure
February 17, 2026 · by Fintool AI Agent
Medtronic delivered its strongest organic revenue growth in 10 quarters at 6.0%, beating consensus on both the top and bottom line, yet shares fell approximately 5% in after-hours trading as investors focused on margin compression and the absence of a guidance raise.
The med-tech giant reported Q3 FY26 revenue of $9 billion (+8.7% reported, +6% organic) versus the Street's $8.86 billion expectation, driven by explosive 80% growth in Cardiac Ablation Solutions—the strongest cardiovascular performance in 10 years (ex-COVID). Adjusted EPS of $1.36 beat consensus by $0.03 (3 cents above midpoint), with geographic performance balanced: high single-digit Western Europe, mid-single-digit U.S. (strongest since FY19 ex-COVID) and Japan, low single-digit China.
Did Medtronic Beat Earnings?
Yes—Medtronic beat on both revenue and EPS for the eighth consecutive quarter.
The beat was driven by broad-based strength across all four operating segments, with Cardiovascular leading at +11% YoY growth—the segment's strongest performance in 10 years (excluding COVID comparisons).
Ask Fintool AI AgentHow Did the Stock React?
Shares dropped ~5% in after-hours trading despite the beat.
MDT closed regular trading at $99.49 (-1.4%) and fell to approximately $95 in after-hours—a 5% decline from the prior close. The negative reaction likely reflects:
- No guidance raise despite strong Q3 results
- Gross margin compression of 170bps YoY to 64.9%
- Tariff overhang with ~$185M expected FY26 COGS impact ($93M in Q3)
- Mix headwinds from faster-growing but lower-margin Diabetes and CAS businesses
The stock has been range-bound between $79-$106 over the past year, with the 52-week high of $106.33 set in late 2025.
What Changed From Last Quarter?
Growth accelerated meaningfully, but margins came under pressure.
Key developments this quarter:
- Hugo RAS received FDA approval for urologic procedures with first U.S. cases completed at Cleveland Clinic
- Stealth AXiS FDA clearance - New transformative spine robotics platform unifying AI-powered planning, robotics, and navigation
- MiniMed IPO S-1 filed with the SEC, advancing the Diabetes business separation
- Sphere-360 secured CE Mark and initiated U.S. pivotal trial
- CathWorks acquisition expected to close by end of FY26
- Touch Surgery installations surpassed 1,000 systems globally, up 20% sequentially
How Did Each Segment Perform?
Cardiovascular: +11% YoY (+13% U.S.)
The star of the quarter. This represents the strongest cardiovascular growth in 10 years (excluding COVID comps). Cardiac Ablation Solutions grew 80% YoY, with PFA accounting for 80% of CAS revenue. Beyond CAS, the remainder of the portfolio delivered combined mid-single-digit growth.
Other Cardiovascular highlights:
- CRM: 5% growth (15% of total revenue), driven by double-digit Micra growth, mid-teens 3830 CSP Lead growth, and 70%+ Aurora EV-ICD growth
- Peripheral Vascular Health: High single-digit growth across endovenous portfolio; NeuroGuard IEP carotid stents and Liberant mechanical thrombectomy launching
- Structural Heart: Low single-digit growth; stronger internationally with continued European share gains, offset by U.S. competitive pressure post-Evolut FX+ anniversary
Neuroscience: $2.56B (+3% organic)
Growth was more modest but has one of the broadest pipelines with exciting opportunities:
- Cranial & Spinal Technologies: Mid-single-digit growth including 8% growth from strong pull-through in Core Spine
- Neuromodulation: 4% growth driven by Inceptiv closed-loop SCS and BrainSense ADVS
- Specialty Therapies: Flat results, but expecting improved performance from new product developments
- Stealth AXiS: New navigation and robotics platform just received FDA clearance—expected to contribute as soon as Q4
Medical Surgical: +3% organic (ahead of expectations)
- Endoscopy: 10% growth led by mid-teens esophageal portfolio growth, driven by Nexpower and strong EndoFlip 300 adoption
- Acute Care & Monitoring: 7% growth led by blood oxygen management and airway access strength
- Surgical: 1% growth with strength in energy, wound management, and hernia, offset by expected stapling softness
- Hugo RAS: FDA cleared for urology with first U.S. installations and cases at Cleveland Clinic; surgeons praising flexibility, portability, open console, and trusted instrumentation
Diabetes (MiniMed): 15% reported, +8% organic
Strong performance ahead of planned separation:
- International: Double-digit strength led international growth
- U.S.: Acceleration with strong sequential lift from Simplera Sync and Instinct (both launched December)
- Pharmacy channel: Seven ATG system now available through pharmacy with agreements covering majority of commercially insured U.S. lives
- Pipeline: MiniMed Flex submitted to FDA; Vivera (third-gen fully closed-loop algorithm) U.S. pivotal study initiated; MiniMed Fit patch pump on track for FDA submission by Fall 2026
- Separation: On track for completion by end of calendar year 2026 via two-step IPO and split
Ask Fintool AI AgentWhat Did Management Guide?
FY26 guidance reiterated—no raise despite the beat.
Management expects similar organic revenue growth in Q4 as Q3 (~6%) and continues to expect gross margin and operating margin leverage in the second half, excluding tariffs.
Key guidance assumptions:
- Continued MSD revenue growth driven by growth driver acceleration
- Gross margin slightly up ex-tariffs with pricing and COGS efficiency execution
- Increased investment in CAS, RDN, and Hugo across R&D and Sales
- Operating profit growth ~5% (or ~7% ex-tariffs) even with significant growth investments
FY27 outlook: Management reiterated commitment to high single-digit EPS growth in FY27, with several puts and takes:
Management noted the Street at 8.5% EPS growth may not fully embed the diabetes and M&A dilution impacts.
What Did Management Say About Key Growth Drivers?
Renal Denervation (Symplicity): Management disclosed compelling leading indicators showing momentum building:
- Website visits: 2.5 million in Q3 vs. 50,000 in Q2 (50x increase) from direct-to-consumer Go Beyond campaign
- New accounts: 200+ opened in the quarter
- Physician finder: 150 physicians (high bar—requires 5+ cases and opt-in)
- Covered lives: 100 million (about one-third of U.S. population)
- Competitive dynamics: "We're doing way better than any of those models" on market share vs. competitor
"The consumer demand is really spiking here... most importantly, we're getting terrific patient results, patient outcomes. With the blood pressure coming down meaningfully, it's staying." — CEO Jeff Martha
UltraViva: 500+ physicians trained, often traveling on weekends—showing strong commitment and demand.
Cardiac Ablation Solutions (CAS): Management expects the EP market to grow at least high teens in FY27 and "strong double-digit" thereafter. MDT remains "very well positioned" with its catheter portfolio and integrated mapping.
"When you look at our competitor, that's really their value proposition centers around catheters, we believe we have a better portfolio of catheters." — CEO Jeff Martha
Stealth AXiS: CEO called this "meaningfully underappreciated" by the investment community. The platform is expected to both take share and expand the robotics market by lowering barriers to entry:
"Today, navigation, which we pioneered and we lead, drives 70% of U.S. spine procedures... The Stealth AXiS fits right into that workflow, so it's one seamless system from the initial imaging to the AI-based surgical planning, right into the case." — CEO Jeff Martha
What Are the Key Risks?
Margin compression remains the primary concern.
-
Tariff Headwinds: ~$185M expected FY26 COGS impact ($93M in Q3, ~$75M expected in Q4), carrying over to ~$300M in FY27
-
Gross Margin Pressure: Q3 gross margin of 64.9% reflects:
- +30bps pricing benefit
- -20bps net inflation/cost down (Q3 typically lowest for efficiency savings)
- -100bps mix (CAS capital equipment vs catheters, Diabetes in early Simplera manufacturing ramp)
- -110bps tariffs
- +40bps FX tailwind
-
CAS Margin Dynamics: CFO noted CAS is slightly dilutive at gross margin level due to capital equipment mix, but "fantastic from an operating margin perspective." Expects gross margin inflection in H2 FY27 as catheter mix improves.
-
Diabetes Separation Execution: Expect $0.01-0.02/month dilution between IPO and full split since share count reduction happens only upon full separation
-
Competitive Pressure in Structural Heart: U.S. saw some pressure post-Evolut FX+ anniversary, though continuing to gain share in Europe
What Catalysts Are Ahead?
Bottom Line
Medtronic delivered an impressive 6.0% organic growth quarter—its strongest in 10 quarters—led by the explosive PFA opportunity in Cardiac Ablation Solutions. Cardiovascular grew 11% YoY, the strongest performance in 10 years (ex-COVID).
However, the lack of a guidance raise and continued margin pressure from tariffs and product mix left investors wanting more. The ~5% after-hours decline suggests the market had higher expectations heading into the print, particularly given the strong growth trajectory.
For long-term investors, the transformation story remains intact with multiple growth drivers at different stages:
- Delivering today: CAS (80% growth), CRM (steady 5% growth), Peripheral Vascular Health (high single-digit)
- Pipeline activating: Symplicity (2.5M website visits), UltraViva (500+ physicians trained), NeuroGuard, Liberant
- Just beginning: Hugo U.S. launch, Stealth AXiS spine robotics
- Work in progress: Structural Heart (filling portfolio gaps via Anteris investment)
Management's confidence in accelerating revenue growth ex-53rd week and high single-digit EPS growth in FY27 suggests they see the growth drivers continuing to compound. The key question is whether CAS and Diabetes margin mix normalizes as expected in H2 FY27, allowing operating leverage to emerge.
Q&A Highlights
On FY27 growth acceleration (Travis Steed, Bank of America): CEO confirmed growth acceleration expected excluding the 53rd week, driven by CST (Stealth AXiS), Neurovascular (On-X, NeuroGuard), Symplicity, UltraViva, and Hugo kicking in.
On CAS market outlook (Larry Biegelsen, Wells Fargo): Management expects the EP market to grow "at least high teens" in FY27 and "strong double-digit" thereafter. On competitive positioning: "When you look at the four players in PFA, I think we're very well positioned... we believe we have a better portfolio of catheters."
On M&A strategy (Patrick Wood, Morgan Stanley): Focused on "tuck-in deals" up to several billion across many segments, prioritizing higher growth areas. May pursue "multiple shots on goal" in must-win markets (like they did with PFA: organic + Affera).
On Hugo timeline (Chris Pasquale, Nephron): CEO expects "step up in Q4" but noted the $6B Surgical business has puts and takes, so Hugo may not move the needle on the total yet—but "underneath the covers, Hugo is growing pretty fast."
On CAS margin inflection (Matt Miksik, Barclays): CFO expects capital-to-catheter mix to "start to see an inflection in the second half of next year" and CAS to drive "gross margin improvement as early as 2027."
Ask Fintool AI Agent